Tag: Tuberculosis
Stratifying by Severity May Allow Shorter TB Tx Regimens
Those with minimal disease may be cured with a four-month versus six-month treatment regimen
Relapse-Free Cure From MDR-TB Higher Than Anticipated
Per simplified outcome definition, frequency similar in low-, intermediate-, high-incidence countries
MICs of Isoniazid, Rifampin May Predict Tuberculosis Relapse
Higher MIC in pretreatment M. tuberculosis isolates linked to relapse risk
Rifampin Effective for Latent Tuberculosis in Children
Rifampin has advantage of being a shorter, single-drug regimen that is palatable for children
Rifampin Similar to Isoniazid for Preventing Active Tuberculosis
Rifampin has significantly higher rate of treatment completion, fewer drug-related adverse events
Completion Likely With Self-Administration of TB Treatment
Self-administration without reminders is noninferior to direct observation in patients with latent TB
Assay Can ID M. tuberculosis Resistance Mutations
Assay detects mutations associated with resistance to isoniazid, fluoroquinolones, aminoglycosides
Change in Conversion Definition May Improve TB Detection
Increase from IFNγ <0.2 to >0.7 IU/mL would improve identification of those at risk of tuberculosis
Meta-Analysis Compares Efficacy of Therapies for Preventing TB
Isoniazid, rifampicin monotherapy, combination therapies can prevent active TB in latent TB infection
Multidrug-Resistant TB Set to Increase Through 2040
Increase in percentage of MDR tuberculosis, XDR tuberculosis in India, Philippines, Russia, S. Africa
